These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25324139)

  • 21. NBS1 is regulated by two kind of mechanisms: ATM-dependent complex formation with MRE11 and RAD50, and cell cycle-dependent degradation of protein.
    Zhou H; Kawamura K; Yanagihara H; Kobayashi J; Zhang-Akiyama QM
    J Radiat Res; 2017 Jul; 58(4):487-494. PubMed ID: 28369484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assembly of functional ALT-associated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1.
    Wu G; Jiang X; Lee WH; Chen PL
    Cancer Res; 2003 May; 63(10):2589-95. PubMed ID: 12750284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular disruption of the MRN(95) complex induces radiation sensitivity in head and neck cancer.
    O'Malley BW; Li D; Carney J; Rhee J; Suntharalingam M
    Laryngoscope; 2003 Sep; 113(9):1588-94. PubMed ID: 12972939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response.
    Wurster S; Hennes F; Parplys AC; Seelbach JI; Mansour WY; Zielinski A; Petersen C; Clauditz TS; Münscher A; Friedl AA; Borgmann K
    Oncotarget; 2016 Mar; 7(9):9732-41. PubMed ID: 26799421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models.
    Hernandez AL; Young CD; Bian L; Weigel K; Nolan K; Frederick B; Han G; He G; Devon Trahan G; Rudolph MC; Jones KL; Oweida AJ; Karam SD; Raben D; Wang XJ
    Clin Cancer Res; 2020 Jun; 26(12):3058-3070. PubMed ID: 32139402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
    Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
    Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purification and Biophysical Characterization of the Mre11-Rad50-Nbs1 Complex.
    Myler LR; Soniat MM; Zhang X; Deshpande RA; Paull TT; Finkelstein IJ
    Methods Mol Biol; 2019; 2004():269-287. PubMed ID: 31147924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template.
    Williams RS; Williams JS; Tainer JA
    Biochem Cell Biol; 2007 Aug; 85(4):509-20. PubMed ID: 17713585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Visualization of local DNA unwinding by Mre11/Rad50/Nbs1 using single-molecule FRET.
    Cannon B; Kuhnlein J; Yang SH; Cheng A; Schindler D; Stark JM; Russell R; Paull TT
    Proc Natl Acad Sci U S A; 2013 Nov; 110(47):18868-73. PubMed ID: 24191051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
    Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
    Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks.
    Williams GJ; Lees-Miller SP; Tainer JA
    DNA Repair (Amst); 2010 Dec; 9(12):1299-306. PubMed ID: 21035407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Replication fork stability confers chemoresistance in BRCA-deficient cells.
    Ray Chaudhuri A; Callen E; Ding X; Gogola E; Duarte AA; Lee JE; Wong N; Lafarga V; Calvo JA; Panzarino NJ; John S; Day A; Crespo AV; Shen B; Starnes LM; de Ruiter JR; Daniel JA; Konstantinopoulos PA; Cortez D; Cantor SB; Fernandez-Capetillo O; Ge K; Jonkers J; Rottenberg S; Sharan SK; Nussenzweig A
    Nature; 2016 Jul; 535(7612):382-7. PubMed ID: 27443740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of ATMIN-DYNLL1-MRN axis in the progression and aggressiveness of serous ovarian cancer.
    Berkel C; Cacan E
    Biochem Biophys Res Commun; 2021 Sep; 570():74-81. PubMed ID: 34273621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MCM8-9 complex promotes resection of double-strand break ends by MRE11-RAD50-NBS1 complex.
    Lee KY; Im JS; Shibata E; Park J; Handa N; Kowalczykowski SC; Dutta A
    Nat Commun; 2015 Jul; 6():7744. PubMed ID: 26215093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interplay with the Mre11-Rad50-Nbs1 complex and phosphorylation by GSK3β implicate human B-Myb in DNA-damage signaling.
    Henrich SM; Usadel C; Werwein E; Burdova K; Janscak P; Ferrari S; Hess D; Klempnauer KH
    Sci Rep; 2017 Jan; 7():41663. PubMed ID: 28128338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
    Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
    Karakashev S; Zhu H; Yokoyama Y; Zhao B; Fatkhutdinov N; Kossenkov AV; Wilson AJ; Simpkins F; Speicher D; Khabele D; Bitler BG; Zhang R
    Cell Rep; 2017 Dec; 21(12):3398-3405. PubMed ID: 29262321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.